Loading…
Platform tested amid Congo outbreak with 246 cases.
Soligenix, Inc. announced that its ThermoVax platform has demonstrated suitability for a vaccine targeting the Bundibugyo virus. This announcement comes amid an outbreak in the Congo, where 246 cases have been reported.
The ThermoVax platform is designed to enhance the thermal stability of vaccines, making them more suitable for use in regions with limited cold-chain infrastructure. The company's progress in this area underscores its commitment to addressing global health challenges.
As of the latest data, Soligenix has a free float of 9,760,578 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.